Clinical Trials Directory

Trials / Sponsors / Beijing Pearl Biotechnology Limited Liability Company

Beijing Pearl Biotechnology Limited Liability Company

Industry · 8 registered clinical trials — 3 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingA Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer
Phase 1 / Phase 22026-06-01
RecruitingA Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
Non-Small Cell Lung Cancer
Phase 32025-07-07
RecruitingA Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Non-small Cell Lung Cancer
Phase 32023-10-16
Active Not RecruitingA Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)
Non-small Cell Lung Cancer
Phase 22020-01-17
Active Not RecruitingA Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusi
Glioblastoma
Phase 2 / Phase 32018-10-08
UnknownPhase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.
Non-Small Cell Lung Cancer
Phase 12016-11-08
CompletedStudy of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliom
Glioma
Phase 12016-09-01
CompletedFirst-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001
Non-Small Cell Lung Cancer
Phase 12016-04-01